Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: Incidence and clinical data

American Journal of Gastroenterology

Volumn 102, Issue 3, 2007, Pages 497-506

  Horwhat, J David ^a,b   Baroni, Darren ^a,b   Maydonovitch, Corinne ^a   Osgard, Eric ^a,b   Ormseth, Eric ^a   Rueda Pedraza, Eugenia ^a   Lee, Hyun J ^a   Hirota, William K ^a   Wong, Roy K H ^a,b,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c Bldg 2 7F43 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BIOPSY; CANCER INCIDENCE; CLINICAL EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DYSPLASIA; ENDOSCOPY; ESOPHAGUS; FEMALE; FOLLOW UP; HIATUS HERNIA; HISTOLOGY; HUMAN; HUMAN TISSUE; INTESTINE CANCER; INTESTINE METAPLASIA; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT RESPONSE;

AGED; BIOPSY; DISEASE PROGRESSION; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; METAPLASIA; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; STOMACH NEOPLASMS; UNITED STATES;

EID: 33847252464     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00994.x     Document Type: Article

References (78)

1. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
2. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
3. Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510-3.
4. Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001;121:1286-93.
5. Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am 1997;26:487-94.
6. Csendes A, Smok G, Burdiles P, et al. Prevalence of intestinal metaplasia according to the length of the specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux. Dis Esophagus 2003;16:24-8.
7. Csendes A, Smok G, Burdiles P, et al. Prevalence of Barrett's esophagus by endoscopy and histologic studies: A prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. Dis Esophagus 2000;13:5-11.
8. Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: Prevalence and clinical data. Gastroenterology 1999;116:277-85.
9. Chalasani N, Wo JM, Hunter JG, et al. Significance of intestinal metaplasia in different areas of esophagus including esophagogastric junction. Dig Dis Sci 1997;42:603-7.
10. Law S, Lam KY, Chu KM, et al. Specialized intestinal metaplasia and carditis at the gastroesophageal junction in Chinese patients undergoing endoscopy. Am J Gastroenterol 2002;97:1924-9.
11. Morales TG, Sampliner RE, Bhattacharyya A. Intestinal metaplasia of the gastric cardia. Am J Gastroenterol 1997;92:414-8.
12. Pera M. Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res 2000;155:1-14.
13. Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg 2003;27:999-1008; discussion 1006-8.
14. Spechler SJ. Short and ultrashort Barrett's esophagus - what does it mean? Semin Gastrointest Dis 1997;8:59-67.
15. Voutilainen M, Farkkila M, Juhola M, et al. Specialized columnar epithelium of the esophagogastric junction: Prevalence and associations. The Central Finland Endoscopy Study Group. Am J Gastroenterol 1999;94:913-8.
16. Voutilainen M, Farkkila M, Mecklin JP, et al. Chronic inflammation at the gastroesophageal junction (carditis) appears to be a specific finding related to Helicobacter pylori infection and gastroesophageal reflux disease. The Central Finland Endoscopy Study Group. Am J Gastroenterol 1999;94:3175-80.
17. Voutilainen M, Farkkila M, Mecklin JP, et al. Classical Barrett esophagus contrasted with Barrett-type epithelium at normal-appearing esophagogastric junction. Central Finland Endoscopy Study Group. Scand J Gastroenterol 2000;35:2-9.
18. Goldblum JR, Richter JE, Vaezi M, et al. Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. Am J Gastroenterol 2002;97:302-11.
19. Peck-Radosavljevic M, Puspok A, Potzi R, et al. Histological findings after routine biopsy at the gastro-oesophageal junction. Eur J Gastroenterol Hepatol 1999;11:1265-70.
20. Trudgill NJ, Suvarna SK, Kapur KC, et al. Intestinal metaplasia at the squamocolumnar junction in patients attending for diagnostic gastroscopy. Gut 1997;41:585-9.
21. Bak YT, Jung GM, Yeon JE, et al. Validity of the specialized columnar epithelium as a diagnostic criterion of the short segment Barrett's esophagus. Korean J Intern Med 1998;13:99-103.
22. Chandrasoma PT, Der R, Dalton P, et al. Distribution and significance of epithelial types in columnar-lined esophagus. Am J Surg Pathol 2001;25:1188-93.
23. Clark GW, Smyrk TC, Burdiles P, et al. Is Barrett's metaplasia the source of adenocarcinomas of the cardia? Arch Surg 1994;129:609-14.
24. Zaninotto G, Avellini C, Barbazza R, et al. Prevalence of intestinal metaplasia in the distal oesophagus, oesophagogastric junction and gastric cardia in symptomatic patients in north-east Italy: A prospective, descriptive survey. The Italian Ulcer Study Group "GISU." Dig Liver Dis 2001;33:316-21.
25. Csendes A, Smok G, Burdiles P, et al. 'Carditis': An objective histological marker for pathologic gastroesophageal reflux disease. Dis Esophagus 1998;11:101-5.
26. Oberg S, DeMeester TR, Peters JH, et al. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg 1999;117:572-80.
27. Oberg S, Peters JH, DeMeester TR, et al. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg 1997;226:522-30; discussion 530-2.
28. Oberg S, Peters JH, DeMeester TR, et al. Determinants of intestinal metaplasia within the columnar-lined esophagus. Arch Surg 2000;135:651-5; discussion 655-6.
29. Zhang J, Chen XL, Wang KM, et al. Barrett's esophagus and its correlation with gastroesophageal reflux in Chinese. World J Gastroenterol 2004;10:1065-8.
30. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
31. Ferraris R, Bonelli L, Conio M, et al. Incidence of Barrett's adenocarcinoma in an Italian population: An endoscopic surveillance programme. Gruppo Operativo per lo Studio delle Precancerosi Esofagee (GOSPE). Eur J Gastroenterol Hepatol 1997;9:881-5.
32. Katz D, Rothstein R, Schned A, et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998;93:536-41.
33. Lipscomb S, Schoenfeld P, Johnston M. The incidence of high grade dysplasia and adenocarcinoma among patients with Barrett's esophagus: A cohort of 154 patients followed for a total of 471 patient-years. Gastroenterology 1999;116:A672.
34. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-42.
35. Robertson CS, Mayberry JF, Nicholson DA, et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988;75:760-3.
36. Sharma P, Morales TG, Bhattacharyya A, et al. Dysplasia in short-segment Barrett's esophagus: A prospective 3-year follow-up. Am J Gastroenterol 1997;92:2012-6.
37. van Sandick JW, van Lanschot JJ, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-22.
38. Weston AP, Krmpotich PT, Cherian R, et al. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: Comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol 1997;92:407-13.
39. Boyce HW. Endoscopic definitions of esophagogastric junction regional anatomy. Gastrointest Endosc 2000;51:586-92.
40. Overholt BF. Acid suppression and reepithelialization after ablation of Barrett's esophagus. Dig Dis 2000;18:232-9.
41. Wesdorp IC, Bartelsman J, Schipper ME, et al. Effect of long-term treatment with cimetidine and antacids in Barrett's oesophagus. Gut 1981;22:724-7.
42. Sampliner RE, Garewal HS, Fennerty MB, et al. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci 1990;35:93-6.
43. Mann NS, Tsai MF, Nair PK. Barrett's esophagus in patients with symptomatic reflux esophagitis. Am J Gastroenterol 1989;84:1494-6.
44. Kothari T, Mangla JC, Kalra TM. Barrett's ulcer and treatment with cimetidine. Arch Intern Med 1980;140:475-7.
45. Iftikhar SY, James PD, Steele RJ, et al. Length of Barrett's oesophagus: An important factor in the development of dysplasia and adenocarcinoma. Gut 1992;33:1155-8.
46. Humphries TJ. Effects of long-term medical treatment with cimetidine and bethanechol in patients with esophagitis and Barrett's esophagus. J Clin Gastroenterol 1987;9:28-32.
47. Cooper BT, Barbezat GO. Treatment of Barrett's esophagus with H2 blockers. J Clin Gastroenterol 1987;9:139-41.
48. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 1990;98:654-61.
49. Weinstein W, Lieberman D, Lewin K, et al. Omeprazole-induced regression of Barrett's esophagus: A 2-year, randomized, controlled, double blind trial. Gastroenterology 1996;110:A294.
50. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997;92:582-5.
51. Shaffer R, Francis J, Carrougher J, et al. Effect of omeprazole on Barrett's epithelium after 3 years of therapy. Gastroenterology 1996;110:A255.
52. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994;89:1844-8.
53. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999;45:489-94.
54. Neumann CS, Iqbal TH, Cooper BT. Long-term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther 1995;9:451-4.
55. LeRhun M, Boyer J, Goldfain D, et al. Long-term omeprazole effects on Barrett's mucosa. Gastroenterology 1996;110:A174.
56. Gore S, Healey CJ, Sutton R, et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993;7:623-8.
57. Cooper BT, Neumann CS, Cox MA, et al. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998;12:893-7.
58. Caldwell M, Byrne P, Walsh T, et al. A randomised trial on the effect of acid suppression on regression of Barrett's oesophagus. Gastroenterology 1996;110:A74.
59. Bologna S, Blumenkehl M, Schubert T, et al. Barrett's esophagus response to long-term omeprazole therapy. Gastrointest Endosc 1992;38:A229.
60. Deviere J, Buset M, Dumonceau JM, et al. Regression of Barrett's epithelium with omeprazole. N Engl J Med 1989;320:1497-8.
61. Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996;44:700-5.
62. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. Am J Gastroenterol 1999;94:3420-6.
63. Wilkinson SP, Biddlestone L, Gore S, et al. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: Results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999;13:1205-9.
64. Sharma P, Weston AP, Morales T, et al. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut 2000;46:9-13.
65. Loughney T, Maydonovitch CL, Wong RK. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus. Am J Gastroenterol 1998;93:916-9.
66. Cameron AJ. Barrett's esophagus: Prevalence and size of hiatal hernia. Am J Gastroenterol 1999;94:2054-9.
67. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999;117:327-35.
68. DeMeester SR, Campos GM, DeMeester TR, et al. The impact of an antireflux procedure on intestinal metaplasia of the cardia. Ann Surg 1998;228:547-56.
69. Bowers SP, Mattar SG, Smith CD, et al. Clinical and histologic follow-up after antireflux surgery for Barrett's esophagus. J Gastrointest Surg 2002;6:532-8; discussion 539.
70. Desai KM, Soper NJ, Frisella MM, et al. Efficacy of laparoscopic antireflux surgery in patients with Barrett's esophagus. Am J Surg 2003;186:652-9.
71. Hofstetter WL, Peters JH, DeMeester TR, et al. Long-term outcome of antireflux surgery in patients with Barrett's esophagus. Ann Surg 2001;234:532-8; discussion 538-9.
72. O'Riordan JM, Byrne PJ, Ravi N, et al. Long-term clinical and pathologic response of Barrett's esophagus after antireflux surgery. Am J Surg 2004;188:27-33.
73. Cobey F, Oelschlager B. Complete regression of Barrett's esophagus after Roux-en-Y gastric bypass. Obes Surg 2005;15:710-2.
74. Morales TG, Bhattacharyya A, Camargo E, et al. Methylene blue staining for intestinal metaplasia of the gastric cardia with follow-up for dysplasia. Gastrointest Endosc 1998;48:26-31.
75. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: International, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-98.
76. Sharma P, McElhinney C, Topalovski M, et al. Detection of cardia intestinal metaplasia: Do the biopsy number and location matter? Am J Gastroenterol 2004;99:2424-8.
77. Dekel R, Wakelin DE, Wendel C, et al. Progression or regression of Barrett's esophagus - is it all in the eye of the beholder? Am J Gastroenterol 2003;98:2612-5.
78. Guda NM, Partington S, Vakil N. Inter- and intra-observer variability in the measurement of length at endoscopy: Implications for the measurement of Barrett's esophagus. Gastrointest Endosc 2004;59:655-8.